NBRVF — Nabriva Therapeutics Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapNeutral

Annual balance sheet for Nabriva Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2018 December 31st	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st
Period Length:	—	—	—	—	—
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Cash and Equivalents
Short Term Investments
Cash and Short Term Investments	102	86.2	41.4	47.7	12.4
Net Total Accounts Receivable
Net Total Receivables	5.37	2.74	3.91	12.8	6.74
Total Inventory
Prepaid Expenses
Total Other Current Assets
Total Current Assets	109	91.2	57.2	80.3	31.1
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	1.14	2.47	0.768	0.233	0.28
Net Intangible Assets
Long Term Notes Receivable
Total Assets	110	94.1	58.4	80.9	31.8
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Current Portion of Long Term Debt / Capital Leases
Total Other Current Liabilities
Total Current Liabilities	17.8	16.6	18.5	22.3	27.6
Long Term Debt
Total Long Term Debt
Total Debt
Total Other Liabilities
Total Liabilities	41.8	52.8	25.3	27.6	28.5
Non Redeemable Preferred Stock
Common Stock
Retained Earnings (Accumulated Deficit)
Other Equity
Total Equity	68.6	41.3	33.1	53.4	3.29
Total Liabilities & Shareholders' Equity	110	94.1	58.4	80.9	31.8
Total Common Shares Outstanding